Search results for "hbv"
showing 10 items of 95 documents
Siero-prevalenza di marcatori di infezione da virus dell’epatite B, C ed HIV in una coorte di immigrati africani a Palermo, Sicilia.
2011
Obiettivi In Italia il 7% della popolazione è rappresentata da immigrati, dei quali oltre 127.000 sono legalmente residenti in Sicilia. Di questi, il 30,3% proviene da Paesi africani, prevalentemente dell’area sub-Sahariana, dove l’epidemiologia delle infezioni virali da virus dell’epatite B (HBV), dell’epatite C (HCV) e dell’immunodeficienza acquisita (HIV) è molto differente da quella europea. Il presente studio è stato condotto per valutare la sieroprevalenza di marcatori di infezione da HBV, HCV ed HIV in una coorte di individui immigrati dall’Africa sub-Sahariana e residenti in Sicilia. Metodi Un’analisi retrospettiva è stata condotta su un panel di 176 sieri, consecutivamente prelevat…
Evolving clinical landscape of chronic hepatitis B: A multicenter Italian study.
2009
The aim of the study was to evaluate the characteristics of chronic hepatitis B with special reference to the geographical origin of the patients and to the prevalence of HBeAg and viral and non-viral co-factors of liver disease. A cross-sectional multicenter survey was undertaken, which enrolled 1,386 HBsAg chronic carriers observed consecutively in 21 referral centers over a 6-month period. The prevalence of HBeAg in patients was 11%; the presence of HBeAg was associated independently with a younger age and co-infection with HIV. Anti-HDV, anti-HCV, or anti-HIV antibodies were detected in 8.1%, 6.5%, and 2%, respectively. However, among the patients first diagnosed during the study period…
Prophylaxis and treatment of hepatitis B in immunocompromised patients
2007
Statements from the Taormina expert meeting on occult hepatitis B virus infection
2008
Giovanni Raimondo*, Jean-Pierre Allain, Maurizia R. Brunetto, Marie-Annick Buendia, Ding-Shinn Chen, Massimo Colombo, Antonio Craxi, Francesco Donato, Carlo Ferrari, Giovanni B. Gaeta, Wolfram H. Gerlich, Massimo Levrero, Stephen Locarnini, Thomas Michalak, Mario U. Mondelli, Jean-Michel Pawlotsky, Teresa Pollicino, Daniele Prati, Massimo Puoti, Didier Samuel, Daniel Shouval, Antonina Smedile, Giovanni Squadrito, Christian Trepo, Erica Villa, Hans Will, Alessandro R. Zanetti, Fabien Zoulim
Kinetics of Anti-Hepatitis B Surface Antigen Titers in Nurse Students after a Two-Year Follow-Up
2020
Infection caused by hepatitis B virus (HBV) can be prevented through a safe and effective vaccine. This study analysed the kinetics of serum antibodies against hepatitis B surface antigen (HBsAg) (anti-HBs) titers in relation to previous vaccine boosters in Italian nursing students who were followed up for two years. Serum anti-HBs titers were evaluated at the first visit, after vaccine booster (if required) and at visit after two years. Overall, 483 students (mean age = 21.7 years
Prophylaxis and treatment of hepatitis B in immunocompromised patients.
2007
The literature on hepatitis B virus (HBV) in immunocompromised patients is heterogeneous and referred mainly to the pre-antivirals era. Today a rational approach to the problem of hepatitis B in these patients provides for: (a) the evaluation of HBV markers and of liver condition in all subjects starting immunosuppressive therapies (baseline), (b) the treatment with antivirals (therapy) of active carriers, (c) the pre-emptive use of antivirals (prophylaxis) in inactive carriers, especially if they are undergoing immunosuppressive therapies judged to be at high risk, (d) the biochemical and hepatitis B surface antigen (HBsAg) monitoring (or universal prophylaxis, in case of high risk immunos…
GENETIC, VIROLOGICAL AND CLINICAL FACTORS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA DEVELOPEMENT IN PATIENTS WITH CHRONIC HBV AND HCV INFECTION
HBV recurrence after HCV clearance on DAAs: Sometimes they come back
2017
Mammalian BiP controls posttranslational ER translocation of the hepatitis B virus large envelope protein.
2008
AbstractThe hepatitis B virus L protein forms a dual topology in the endoplasmic reticulum (ER) via a process involving cotranslational membrane integration and subsequent posttranslational translocation of its preS subdomain. Here, we show that preS posttranslocation depends on the action of the ER chaperone BiP. To modulate the in vivo BiP activity, we designed an approach based on overexpressing its positive and negative regulators, ER-localized DnaJ-domain containing protein 4 (ERdj4) and BiP-associated protein (BAP), respectively. The feasibility of this approach was confirmed by demonstrating that BAP, but not ERdj4, destabilizes the L/BiP complex. Overexpressing BAP or ERdj4 inhibits…
Adefovir for lamivudine resistant HBV: More than meets the eye
2007
– In patients with LAM resistance and high levels of HBV-DNA, especially if HBeAg positive, it may be difficult to obtain a strong virological suppression with ADV. – Restrictive criteria are needed to define virological response (HBV-DNA < 10 3 copies/ml or 200 IU/ml). – Early finding of non-response or of suboptimal response after 9–12 months of ADV therapy suggests a high risk of emergence of ADV-resistant strains and should prompt a change of treatment strategy. In patients with cirrhosis, due to the risk of liver failure, treatment changes should be considered even earlier, at 3–6 months.